Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo aims to erase last traces of leukemia

NCT ID NCT07052695

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times

Summary

This study tests whether the drug mosunetuzumab, given alone or with a BTK inhibitor, can clear tiny amounts of leftover leukemia cells in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 40 adults who are already on or have recently finished treatment will receive the study drugs. The goal is to see if this approach can make the cancer undetectable in the bone marrow.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham & Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.